gap junction O P Q R !S T U LV

(1)

!"# $

% & ' !()* + , - . / 0 12# 3 4 5 1!6 7 81-2 µm^! ⁹ ⁸10-20 µm^!: ^; ^< ⁼ tight junction>gap junction' ?

@ A !B C D ! E F G H IJ K LM $ ! N " gap junction O P Q R !S T U LV/ W X V0 ' Y Z [ \ # 3

F F ] S ^ _` ab c d +e f !g Eh i Vj k \

% lVm no p !q; !r s t u v w x y z V{ ||

}!~ V (Jaffe et al., 1973; Price & Loscalzo, 1999)^/ RossGlomset1973^{ (Response to Injury Hypothesis)/o p Vqa. z

" 7 V =+ ¡ ¢ £ ¤/b.^j ^k ^¥

¦ § ¨ F © [ ª ¤/c. i \ « ¬ ® ¤/«A q¯°

' ± a!² ³ ´ Vu µ 1¶ (Homeostasis)/ V

· H ¸ ¹ º H I(» ¼ ICAM-1VCAM-1E-selectin½)!

¯ EV F «V¾ ¿ À Á Â!Ã § ¹ Ä Å i /; Æ

LÇ ¥È É !(=ÊG H IË g LM(ÌLDL)!Í ÆÊ F Î § Ï

Ð Ñ < !Ò0 ' Ó Ô !Õ Ô LDL Ö $ × Ø !

Ã C 0 ' Ù Ú foam cell¤/Û Ü Ý m nÌMCP-1¤Þ !ß à á

Ü F â à ã Ç !C ÒVÓ ä ¯Þ å æ ç £ ÌTNF-α

IL-6 ½¤!C Êz è á É é /êë ì í t î ï , E$ Î § Ï

$ È 0 ' ð r ñ fibrous cap¤ò ó !Ê ô õ ! h ö g LM/

÷Ù Ú Ex n× Ø MÜ ø ù ú û !ü ý þ , ³ ³ !

Ê à 0 ' X /% =1999Ross ^a ⁱ ¹

2ç ¥e f 1-1¤(Glass & Witztum, 2001; Ross, 1999; Ross &

(2)

Glomset, 1973)^/

(3)

"; ( ! F , V¹ Ä Î i i 1V ë q

!" H ¸ · V¹ º H IÝ m n+ £ º |V

/

¹ º H I

B C D !¹ º H IV 2Ã § < þ n n¹ Ä ^

_!(= µ V H +Î § /÷ ¯È É ¹ Ä ^ _C

Ã F Vã Ç !! " li 1V0 ' (Hillis & Flapan, 1998)^/x

z # M$ % V¹ º H I& |'( (Collins et al., 1995; Price &

Loscalzo, 1999)

1.Integrins^)"* ^- ^' ^V+ ^# ^!» ^¼ α^,+β^,^!(H ²LFA-1

lymphocyte function-associated antigen-1^¤Mac-1VLA-4Very late activation antigen-4^{¤!- .} ^H ^I ^· ^F ^«!(=/ ⁰ ^< ^þ ¹ m nV¹ Ä !^ 2CAMs^VS ² ³counter receptor^¤!Ê ⁴ ^Á Â(Hynes & Lander, 1992)/

2.Selectins^)& ^|5 ⁶ ^Âm ^+* ^Á ^{Â!H 7} L-selectinLymphocytes H ¸ ¤P-selectinPlatelets^H ^¸ ^¤=+E-selectinEndothelial Cells^H ^¸ ^¤ 'ç /& |V 28 9 (Tethering) F l $ !¹ Ä \ : !; 2<

= ¹ Ä êÞ å !Ê > , Å i Rolling^¤/

3.Immunoglobulin Superfamily⁾

ICAM-1Intercellular cell adhesion molecule 1, < ¹ º H I-1¤

F «VLFA-1Lymphocyte function associated antigrn-1¤Á Â C ¹ Ä «!? @ F «VÎ § (Trafficking)/A þ B ICAM-2ICAM-3 H 7 · F + < ¹ º H I(Adams & Shaw, 1994)/

(4)

VCAM-1Vascular cell adhesion molecule 1, ^¹ ^º ^H ^I-1^¤

Å i Vì í E(Rolling)^!( ^F ^«VVLA-1Very late activation antigen-1¤Á Â!ÊC F á D VÁ Â , «/

ÖE F Vþ ã ^ _Extravasation^¤(Zeng et al., 2002)^/

PECAM-1Platelets cell adhesion molecule 1, ^¹ ^º ^H ^I¤

& | F " È É G H æ ç ¹ º H I V Ò ¥ ! Ö E I F tansmigration^Ï ^Ð ^$ ^/

% =CAMsV & |^ _ F «V¹ Ä Å i ! º

D ¹ º ! êþ ã l Ð $ /

'MCP-1(Monocyte chemotactic protein-1 # 3 F Ý -1)

MCP-1 2ç £ ¯l LDL+ £ ¢ £ C Þ å !J

F LÇ Ð $ K ¯¢ £ H ¸ !L M á Ü F â à l N

/O G P Q R 2 MCP-1 ST ù i 1U V qIT % ¥!q

; F W b MCP-1^ 2e f X Y (Deo et al., 2004)/Z [ P Q \] ^ _x`

a z b MCP-1 \º c b !ö µ x` a _3 á d µ

(Aukrust et al., 2001)/i m e f g _ qh i j ª k ÌApoE ^l ^m ^k ApoB M7· k ½¤^ 2i 1 n P Q o p ! l m MCP-1>CCR2 F «VMCP-1 receptor¤êq r s r !b t - T u d (\º v w & i Ó ä â à +v w Ù Ú 0 ' V x !yz

J o p (Boring et al., 1998; Gosling et al., 1999; Han et al., 1999)/b {

| } HUVECs^¤~ fibrates ^m ^(\º ^v ^w ^" CRP ^ø MCP-1V· (Pasceri et al., 2001)!\] MCP-1¯PPARÒ ab !

(2v w i 1 ë F â à |v w j t /

(5)

TNF-αtumor nerosis factorα ^ú ^û ^qIα)

2Ü £ !(ab H c d e f + !

´ ú û qIpro- TNF-α^¤TNF-α converting enzymeTACE¤ H Z ' !" 157 ⁺ - ' !& |F "+ À TNFR1 & 2(Tumor Necrosis Factor Receptor 1 & 2 )!÷TNF-α ^À ^Á ^ÂÆ!(=Ò+

& |Vh qI)NF-κB ⁺ AP-1^!Ö ^ø ^qE ^¥+ ^¥e ^f (Aggarwal, 2000)^/TNF-α^& ^|¯l " z LPS^¤

> 1¶ C ' / t î ï +Ó Ô ¯H ¸ TNF-α^!L

"Ò Ó ä Þ å ê e f ! Ã È É LÇ

¥H ¸ ST £ qI! \ È É æ ç ¹ º H IH ¸ V e f

£ pro-inflammation cytokines¤(Zeng et al., 2002)/

P Q \] !TNF-α^K ^¯È ^É ^Ò¥ ^m ^ç reactive oxygen species,ROS^¤ C È É ® \ !ÊNF-κB AP-1ÒC È É ICAM-1VCAM-1V· ! C ( t TNF-α ^ø NF-κB^{Ò!v w} ICAM-1VCAM-1 mRNAV· !Ã C v w # 3 F V¹ Ä (Chen et al., 2003; Weber et al., 1994; Wertheimer et al., 1992; Zapolska-Downar et al., 2004)/ApoE^l ^m J TNF-α ^l ^m ^k ^V& ⁱ ^Ø ^\º ApoE ^l ^m ^k !

ICAM-1VCAM-1+MCP-1 · d (Ohta et al., 2005)/"; ( TNF-α

, + ù 1i 0 ' V !(c a up-regulated¤

¹ º H I £ V· /

NOnitric oxide, ¤eNOSendothelial nitric oxide synthase,

Â' ¤

i m ¥ NO ¡ H N æ - . E!("'ç ö Í p NOS % Â' !H 7 nNOSneuronal nitric oxide synthase,^¢ ^F NOS¤iNOSinducible nitric oxide synthase, ø NOS ¤ + eNOS

endothelial nitric oxide synthase, NOS^¤^/NO ^| ^ö ^' ^z ^£ ^I ^J

¨ H I!L-arginine2n! H I2¤ nco-substrate¤!¥ |NADPH

(6)

nicotinamide-adenine-dinucleotide phosphate ^¤ FAD flavin adenine dinucletide^¤BH46R^¤-5,6,7,8-tetrahydrobiopterin^{¤ +} FMNfalvin mononucleotide¤^ 2¤ co-factor¤/

$ VeNOS 1991^¦ ^§ ^` (Kubes et al., 1991)^! ^F ^¨ ^©

ª « ¢ £ « À ! Ên¬ ® Þ å ! ¯ ° ± ® ²

7!Òcalmodulin ^n!C ^êÒeNOS^!Ã ^C ^Â' NO(Mollace et al., 2005)^/ ^E ^' ^V NO ^qW ^³ ^´ ^µ ^¶ ^[ ^Va ^!¦ ^R ²

· ¥¶ [ qIendothelial derived relaxing factor,EDRF¤(Palmer et al., 1987)/m r s ¶ [ \ !a ® þ ! (= t " cGMP ø z

¶ [ ¢ £ ¸ vasodilator-stimulayes phosphoprotein,VASP¤ ¸

! t fibrinogen receptor¹ F z ¹ º t î

ï È º Î » G ¼ ½ ¾ ^ _!Öv w LDL à

MCP-1IL-6IL-8M-CSFmacrophage coloy-stimulating factor¤ICAM-1 VCAM-1E-selectin =+ NF-κB ^VÒ¥!¿ ^l¹ ⁱ ^1e ^Vj

¯!~ NO ^t T VÁ À !Á 2 i qI(De Caterina et al., 1995; Kubes et al., 1991; Peng et al., 1995; Venema, 2002; Zeiher et al., 1995)/ ª Â Ã n ® L Ä z =+Å x y z Æ Ç È z b e É ± aV x !"NO^V¹ ^x ^y ^z ^e

V% Ê !q; ¦ R 2S Â' Ë 2& |Ì µ V|}!(John et al., 1998; Napoli & Ignarro, 2001; Suwaidi et al., 2000; Werns et al., 1989)!"

; ( !eNOSÂ' NO^z V µ +v w 1i Í H |/

(7)

2-2eNOS^Á ^& ^ÒÎ (Musicki & Burnett, 2006)

^|ÒeNOS^Ï ^Ð ^Ñ ^VÁ ^& ^¾ ^¿ ^ÒÒ ^Ó ^% 2-2^¤^/eNOS + Ô Õ £ P450^Vhemoprotein^{!Á &} ^«Å ^B ^´ ^Ö ⁺ ^× ^E x!Ø Ca²⁺/calmodulin-dependent ^Ù ^{!Ú Û} caveolae^«

caveolin-1^Á ^Â2ö ^Ò¶ ^!¥ ^|Ca²⁺^a ^ÊeNOScaveolin-1^H ^± ^ê(Boo &

Jo, 2003; Busse & Fleming, 2003)^{! Ã} ^§ ^h ^Ü ^{ê Ý} ^Þ posttranslation modification^¤!Ì¸ /^¼ ^¸ ^j ^t ^` ^ab ^Ù ^Ò¥!SÒ¥Ü ⁺ protein kinase^a ^¾ ^¬ ^{¥ ¸} ^Î Serine⁺Threonine residues^{! »} ^¼ AMP-activator protein kinasecAMP-dependent protein kinaseAkt/protein kinase Bprotein kinase C⁺calmodulin-dependent kinase ^ß activator(Chen et al., 1999; Michell et al., 2001; Zhang & Hintze, 2001)^!Ser-1177^2 Ã eNOS^Ò

¸ ¾ ¬ Î !Thr-495² ^t eNOS^Ò ^¸ ^¾ ^¬ ^Î ^!G ^Ü ^à á â X ¸ Ser-1177^+¼ ^¸ Thr-495 ^& ^|a eNOS^Ù ^ÒVã ä!% =F =H å pSer¹¹⁷⁷eNOS⁺pThr⁴⁹⁵eNOS ^· ^æ ^` ^ç ^è ^Ù ^é

lÒ(Fulton et al., 2001; Harris et al., 2001; Michell et al., 2001)^/y ^S T á â l Ã eNOS^Ù ^Ò¥ ^¸ ^Î ^m ^ê Ser-1177 ^{þ !B ST} ^Ò

Î » ¼ Ser-615⁺Ser-633^!Í ^ë ^( Ã eNOS^Ù ^Ò(Bauer et al., 2003;

Boo et al., 2003; Michell et al., 2001)^/

(8)

ìNF-κBNuclesr factor-κB,³ ^qI-κB^¤

G N H V e f Iκ-B/ NF-κB ^ab ^/i ^, ^n×

Ø N u B c , d Ü ÒVNF-κB^{!ö í} ^{t î} ^ï ^Ó ^ä

« · !S ¯ab Ð ° q· !q; Jî 2 qh qI/

NF-κB^ï ^nE!ØRel^Æ ^ð ^Vç ^n!"Ö ⁺ ^¬ ^& p50 +p65^% ^- ^{' /}NF-κB ^ê ^e ^f ^> ^® ^\ ^² ^³ ^ÆQ ^R ^O ^P ^V ^/

÷ ñ ¢ £ ò ó Ð !NF-κB I-κB ^µ ^Á ^Â!y ^÷ ^l¢ ^£ Æ!Protein Kinase CÒÊI-κB^e ^¸ Phosphorylation¤ÖNF-κB

ô ± H Z /¦ Ò NF-κB ^¯õ ^M3 ^ö ^Ã ^÷ ³ ^Ö ^qø ^A ^E

i IPromoter¤V κB ^Î ^Á ^Â!ù ⁱ ^I% ^b ^t ^qø ^A ^· ^Öh

T % V mRNA=+ú ° % Ø V n!» ¼ TNF-αIL-1βMCP-1 M-CSFICAM-1VCAM-1½1-2,1-3¤(Baeuerle & Henkel, 1994; Brand et al., 1996; Collins, 1993; Cramer & Muller, 1999)/

û ü K ý þ NF-κB ^Ú ^Û ^O ^Y ^q«!(v ^w ⁱ ^1T ^%

V n· !v w x y z Ve !q; O G G Ü à 3 : \ P Q Ì

t NF-κB ^VÒ!Ì PPARs activator + NO N ; j t ab e f V i 1qI!( Ç MÒ I-κB ⁹ ^>v ^w ^¬ ^& p50 + p65 V ' ` ¿ ' /

(9)

2-3 IκB/ NF-κB^ab (Cramer & Muller, 1999)

2-4 NF-κB/Relⁱ ^1z ^# ^j ^o (Brand et al., 1996)

(10)

PPAR

M È i ÒÀ PPAR

1990 ⁺ ^M ^È ⁱ ^{Ò À} peroxisome

proliferators-activated receptor,PPAR^¤ ^k ^E ⁱ ^` ^!Ö ^S steroid/thyroid/vitamin D ^Í ^A ³ ^À ^Æ ^ð nuclear hormones receptor superfamily¤V' ! ¦ R V PPARÏ w PPARαPPARβ^Jî ² PPARδNUCIFAAR^¤+ PPARγ ^'ç ^/PPARα ^& ^|·

- . x + ï /PPARβ^æ ^- ^. ^· ^!y=

+x · /PPARγ^& ^|· ^- ^{. !w N} ^H ^Á ^{c d}

+ ¬ ö /q2 ¦ M È i (peroxisome proliferators,PP)^Ò

!% =¦ 2PPAR/

PPARs ligand¤Ò activator¤ã ` (H 2Â' ¥+

¥/÷PPAR >Ò Òê!¯9-cis 9-cis retinoic acid¤ VÀ RXR (retinoic acid receptor)0 ' ¬ & heterodimer¤! Í Ú Û O Y qVPPREperoxisome proliferators-responsive element¤«!ab Ð

° V qh 2-2¤(Kersten et al., 2000)/

2-5 PPAR/RXR^Òj ^t

(11)

PPARs ⁱ ^VT ^% ^¥

! ¯V " y z Ì n i 1 z +» # L ö

# e !C $ % & ' V " ( ) !î 2 " n * ( Snydrome X¤/

Z [ «F Ê_Â' ¥ PPAR activator ⁺ ^, ^" ⁿ ^* ⁽ ^!Ì TZDsPPARγ ligand^¤fibrates ^Õ ^m PPARα ligand^¤H ⁷ ^2¹ ^_ ^/O ^G fibrates ^m ^m ^ê ^& ^| ^_Z ^[ ^z ^_¹ ⁺ ^, ^þ ^!_+

, x y z «/ TypeΠb ⁿ ⁺ⁱ ^z ^b fibrates ^Õ ^m ⁺ ^,

+ - !ö ; ² . !K \º ¹ / E TNF-α IFNγ (Madej et al., 1998)/

q r 0 0.51ª Â Ãs r V2 I 0.111 fenofibrate 30mg/kg/day¤ 3 ÷ 4 5 E!246ê(¹ 7 & i PPApercentage of plaque area¤V 0 ' !yz J o p !8 9 fibrates ^Õ m , Å i 1

V: !( ; < ¹ V \ (Saitoh et al., 1995)/

PPARαγ ^K ^{¯ ·} SMCsECs¤ + e f

monocyte/macrophage¤!SE V PPARα^· ^Ë PPARγ^!~ æ ç PPARs activator e = PPARα activator ⁽ ^t ^H ^¸ VCAM-1!Öo p F V] S ^ _!yz ICAM-1E-selectin J o p (Jackson et al., 1999)/Delerive ½b e fibrates ^Õ m ( t b &

i t î ï human aortic smooth-muscle cells,SMC¤IL-1β^¢ ^£ ^H ^¸ IL-6/PPARα^l ^m ^k PPARα-/-^¤¯z LPS¢ £ > ? @ ¥Ve f !

fibrates ^ê!A ^k PPARα+/+^¤ ^G ⁱ IL-6 mRNA^· ^\º

¹ !y PPARα ^l ^m ^k PPARα-/-^¤ÖJ ^: ^À ^!\] PPARα activator V N "a PPARα^¿ ^l ^e ^f ^V ^: ^/Ò PPARα ^B ⁽ ^t c-Jun ⁺ p65 ^ø IL-6 promotor^h ^!q; ⁸ ⁹ PPARα⁽ ^N ^"B ^C AP-1⁺NF-κB

` t e f (Delerive et al., 1999)/ !á Ã Ò e f 8 9 PPARα activator ^Ç ^M Ã I-κB ^V· ^C ^ý ^D NF-κB ^Ú ^Û ^O ^Y ^q 2-3^¤ (Delerive et al., 2000)^{/T Í} ^{V! _b} ^E ^} Human saphenous

(12)

vien endothelial cells^¤=fenofibrate 100 µmol/L^F ^# 24 ^Æê!
É ^÷ TNFα 10 ng/mL^¢ ^£ 8 ^Æ!(\º ^¹ VCAM-1^H ^¸ ^¿ 33±9¹p^G0.01^¤^!Ö v w U937 cells ¹ º Và O !Öý D NF-κB ^Ò(Marx et al., 1999)^/

H «% H !PPARα ^, ^e ^f ^j ^h ^« ^|V ^!û ^I s r EJ C ¥VPPARα activator^{!ö ;} ^(K ^c ^Â' ^¥ ^_ ^Ë ^« V ¥L ^ _!B M T Í VN F /O ÌP Q CLAconjugated linoleic acid¤phytanic acid =+Ð e f R _VS T U ½! V W e 2 ¥V PPARα activator (Chao & Huang, 2003; Dallongeville et al., 2001; Heim et al., 2002; Moya-Camarena et al., 1999)^/

2-6 PPARα^Ò ^t NFκB^Q ^X ⁹ ^o ^p ^/